Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GluBio Completes $22 Million Funding for Protein Degradation Candidates

publication date: Aug 1, 2022

GluBio Therapeutics, a San Diego-Shanghai company, completed a $22 million Series A+ financing to advance its early-stage portfolio of targeted protein degradation (TPD) candidates. Earlier this year, the company closed a $50 million Series A round. TPD uses bifunctional chemistry to create chimeric molecules that bind to a protein and tag it for degradation. GluBio will use the capital to move two molecular glue degraders with best-in-class potential into the clinic for hematological malignancies. The A+ round was led by Qiming Venture Partners and included Lilly Asia Ventures and Kaitai Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital